ArticleProceedings of the National Academy of Sciences of the United States of America2006
Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 256 citations in OpenAlex.
- Assessment of Enterococcus faecalis biofilm response to amoxicillin and ciprofloxacin using a dynamic in vitro pharmacokinetic-pharmacodynamic model of catheter-associated urinary tract infection.The Journal of antimicrobial chemotherapy · 2026Article
- Sub-Minimum Inhibitory Concentrations of Amoxicillin Modulate Biofilm Formation and the Expression of Biofilm-Associated Genes inMolecules (Basel, Switzerland) · 2026Article
- Antibiofilm compounds from Streptomyces Labedae 20PM improves survival of and prophylactic effect of Nile tilapia (Oreochromis niloticus) challenged with Aeromonas hydrophila.BMC research notes · 2026Article
- Streptomyces secretes a siderophore that sensitizes competitor bacteria to phage infection.Nature microbiology · 2025Article
- Presence of a biofilm beneficiary alters the evolutionary trajectory of a biofilm former.The ISME journal · 2025Article
- Article
- Role for RTX-family toxin HlyA of extraintestinal pathogenicFEMS microbes · 2025Article
- Glyphosate effects on growth and biofilm formation in bee gut symbionts and diverse associated bacteria.Applied and environmental microbiology · 2024Article
- Synergy between Group 2 capsules and lipopolysaccharide underpins serum resistance in extra-intestinal pathogenicMicrobiology (Reading, England) · 2024Article
- Bacterial capsules: Occurrence, mechanism, and function.NPJ biofilms and microbiomes · 2024Review
- Bacterium secretes chemical inhibitor that sensitizes competitor to bacteriophage infection.bioRxiv : the preprint server for biology · 2024Article
- Bacterial adhesion inhibition by microalgal EPSs from Cylindrotheca closterium and Tetraselmis suecica biofilms.Applied microbiology and biotechnology · 2024Article
- Latent evolution of biofilm formation depends on life-history and genetic background.NPJ biofilms and microbiomes · 2023Article
- Bacterial capsular polysaccharides with antibiofilm activity share common biophysical and electrokinetic properties.Nature communications · 2023Article
- Antibiofilm activity from endophyte bacteria, Vibrio cholerae strains, and actinomycetes isolates in liquid and solid culture.BMC microbiology · 2023Article
- Article
- Synergy of R-(-)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation.Scientific reports · 2022Article
- An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents.Life (Basel, Switzerland) · 2022Review
- The Chemical Profiling, Docking Study, and Antimicrobial and Antibiofilm Activities of theMolecules (Basel, Switzerland) · 2022Article
- Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of surface-attached biofilm bacterial communities is considered an important source of nosocomial infections. Recently, bacterial interference via signaling molecules and surface active compounds was shown to antagonize biofilm formation, suggesting that nonantibiotic molecules produced during competitive interactions between bacteria could be used for biofilm reduction. Hence, a better understanding of commensal/pathogen interactions within bacterial community could lead to an improved control of exogenous pathogens. To reveal adhesion or growth-related bacterial interference, we investigated interactions between uropathogenic and commensal Escherichia coli in mixed in vitro biofilms. We demonstrate here that the uropathogenic strain CFT073 and all E. coli expressing group II capsules release into their environment a soluble polysaccharide that induces physicochemical surface alterations, which prevent biofilm formation by a wide range of Gram-positive and Gram-negative bacteria. We show that the treatment of abiotic surfaces with group II capsular polysaccharides drastically reduces both initial adhesion and biofilm development by important nosocomial pathogens. These findings identify capsular polymers as antiadhesion bacterial interference molecules, which may prove to be of significance in the design of new strategies to limit biofilm formation on medical in dwelling devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.